Amgen’s Pavblu (aflibercept-ayyh) is the fifth biosimilar referencing Eylea (aflibercept) to be approved for American patients with retinal diseases.
The FDA has approved Pavblu (aflibercept-ayyh), the fifth biosimilar referencing Eylea (aflibercept).1 The new product is approved for the treatment of retinal conditions, including neovascular age-related macular degeneration (wet AMD), macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.
Pavblu was developed by Amgen and comes shortly after the FDA approved Enzeevu (aflibercept-abzv) in August 2024.2 All 5 aflibercept biosimilars were approved in 2024, beginning with Biocon Biologics's Yesafili (aflibercept-jbvf) and Samsung Bioepis' Opuviz (aflibercept-yszy) in May 2024, followed by Formycon and Klinge Biopharma’s Ahzantive (aflibercept-mrbb) in July 2024 and Enzeevu.3,4
The approval was based on data from a randomized, double-masked, phase 3 study (NCT04270747) assessing the safety and efficacy of Pavblu (ABP 938) compared with Eylea in patients with wet AMD.5 Overall, 566 patients across 126 global sites were randomized 1:1 to receive 2 mg (0.05 mL) intravitreally of either ABP 938 (Treatment Group A) or aflibercept (Treatment Group B).
The final cohort included 576 patients from 102 centers Canada, Czech Republic, Estonia, Germany, Hong Kong, Hungary, Israel, Italy, Japan, the Republic of Korea, Latvia, Lithuania, Poland, Slovakia, Spain, and the US between June 22, 2020, and January 30, 2023. A majority of the patients were women and 86% were White.
This study included a screening period of up to 4 weeks, followed by 48 weeks of treatment with the investigational product, and a safety follow-up through week 52, for a total study duration of up to 56 weeks. The primary endpoint was evaluated at week 8, measuring the change in best corrected visual acuity using the early treatment diabetic retinopathy study letter score from baseline to week 8 to assess the efficacy of ABP 938 compared to aflibercept.
At week 16, subjects were re-randomized in a masked manner as follows:
The study found no clinically meaningful differences between the 2 products, demonstrating the biosimilarity of ABP 938 compared with the reference agent.
Aflibercept Legal Battle
Amgen and Regeneron, the maker of Eylea, are currently involved in a Biologics Price Competition and Innovation Act lawsuit concerning Pavblu.6 On August 13, 2024, a preliminary injunction hearing was held to determine whether Amgen will be blocked from launching Pavblu at-risk. The court’s decision is still pending.
In the filing, Regeneron alleges that Amgen infringed 32 patents covering the manufacturing and use of Eylea when developing Pavblu.
Regeneron has filed similar lawsuits against other biotech companies attempting to develop Eylea biosimilars. In December, a federal judge in West Virginia ruled that Viatris' proposed biosimilar infringed on Regeneron's patent rights.7
References
1. Fifth Eylea® biosimilar FDA-approved: Amgen’s Pavblu™ (aflibercept-ayyh). Venable. August 29, 2024. Accessed September 16, 2024. https://www.jdsupra.com/legalnews/fifth-eylea-r-biosimilar-fda-approved-6326603/
2. Jeremias S. FDA approves biosimilar Enzeevu for eye conditions. The Center for Biosimilars®. August 12, 2024. Accessed September 16, 2024. https://www.centerforbiosimilars.com/view/fda-approves-biosimilar-enzeevu-for-eye-conditions
3. Jeremias S. FDA approves first Eylea biosimilars. The Center for Biosimilars. May 20, 2024. Accessed September 16, 2024. https://www.centerforbiosimilars.com/view/fda-approves-first-eylea-biosimilars
4. Jeremias S. Ahzantive receives FDA approval as new Eylea biosimilar. The Center for Biosimilars. July 1, 2024. Accessed September 16, 2024. https://www.centerforbiosimilars.com/view/ahzantive-receives-fda-approval-as-new-eylea-biosimilar
5. A study to understand effectiveness and safety of ABP 938 compared to aflibercept (Eylea®) in patients suffering with neovascular age-related macular degeneration [neovascular (wet) AMD]. Clinicaltrials.gov. Updated January 5, 2024. Accessed September 16, 2024. https://clinicaltrials.gov/study/NCT04270747
6. Britain B. Regeneron asks US court to block Amgen's Eylea biosimilar. Reuters. January 11, 2024. Accessed September 16, 2024. https://www.reuters.com/legal/litigation/regeneron-asks-us-court-block-amgens-eylea-biosimilar-2024-01-11/
7. Becker Z. Regeneron fends off Viatris' Eylea biosimilar with patent win. Fierce Pharma. December 29, 2023. Accessed September 16, 2024. https://www.fiercepharma.com/pharma/regeneron-fends-viatris-eylea-biosimilar-patent-win
AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1
September 18th 2024Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and highlighting the success of expansion policies for these products, according to a new report from the Association for Accessible Medicines (AAM).
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
BioRationality: FDA Clarification Provides New Indications and Process Change for Biosimilars
September 9th 2024Sarfaraz K. Niazi, PhD, explains the FDA's new guidelines on post-approval changes for biosimilars, emphasizing the processes for reporting modifications, comparability assessments, and the potential for biosimilars to introduce new indications or formulation changes, which could significantly impact their market competitiveness and accessibility.
The Role of Coverage Strategies in Biosimilar Market Impact and Cost Savings
September 4th 2024A recent study highlights that although biosimilars have led to significant price reductions, originator products with sole preferred coverage strategies have maintained market share, suggesting that increased biosimilar uptake alone may not fully leverage the market's competitive and cost-saving potential.